Lung Cancer Clinical Trial

Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer


RATIONALE: Lometrexol may stop or slow the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Folic acid may be effective in preventing or lessening the side effects of lometrexol. Combining lometrexol with folic acid may be an effective treatment for non-small cell lung cancer.

PURPOSE: Phase II trial to study the effectiveness of combining lometrexol with folic acid in treating patients who have stage IIIB or stage IV non-small cell lung cancer that has been previously treated.

View Full Description

Full Description


Determine the overall response rate in patients with previously treated stage IIIB or IV non-small cell lung cancer when treated with lometrexol and folic acid.
Determine the complete response rate, duration of response, and time to progression in patients treated with this regimen.
Determine the 1-year survival rate and overall survival in patients treated with this regimen.
Determine the safety profile of this regimen in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral folic acid once daily on days -7 to 6. Patients also receive lometrexol IV over 30-60 seconds on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Patients are followed up to 2 months after removal from study and then every 3 months thereafter.

PROJECTED ACCRUAL: A total of 50-100 patients will be accrued for this study.

View Eligibility Criteria

Eligibility Criteria


Histologically confirmed non-small cell lung cancer (NSCLC)

Stage IIIB or IV

Squamous cell carcinoma
Large cell carcinoma
Adenosquamous carcinoma
Progressive disease after receiving 1 cisplatin- or carboplatin-containing regimen for stage IIIB or IV disease

Measurable disease

At least 1 lesion at least 1 cm x 1 cm by CT scan either not in a previously irradiated field or showing clear evidence of disease progression after radiation
No symptomatic or rapidly increasing, moderate or large amounts of pleural effusion or ascites
No prior or concurrent CNS metastases (brain or meningeal)



18 and over

Performance status:

Karnofsky 70-100%

Life expectancy:

At least 3 months


Absolute neutrophil count at least 1,500/mm^3*
Platelet count at least 100,000/mm^3*
Hemoglobin at least 9.0 g/dL*
*Without transfusions or growth factors in the previous 7 days


Bilirubin no greater than 1.5 times upper limit of normal (ULN) (regardless of liver involvement secondary to tumor)
AST and ALT no greater than 2.5 times ULN (5 times ULN if liver has tumor involvement)


Calculated creatinine clearance at least 60 mL/min using Cockroft and Gault formula


No inflammatory bowel disease
No radiation enteritis
No malabsorption syndrome
No inability to absorb folic acid


Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during study
No known untreated vitamin B12 deficiency
HIV negative
No drug abusers
No prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
No severe concurrent disease or major comorbidity that would preclude study participation


Biologic therapy:

At least 3 weeks since prior biologic therapy for NSCLC and recovered from acute side effects
Prior treatment with an experimental vaccine allowed
No concurrent routine or prophylactic filgrastim (G-CSF), sargramostim (GM- CSF), or epoetin alfa


See Disease Characteristics
At least 3 weeks since prior chemotherapy for NSCLC (6 weeks for mitomycin or nitrosourea) and recovered from acute side effects
Prior adjuvant or neoadjuvant chemotherapy allowed

Endocrine therapy:

Not specified


See Disease Characteristics
Recovered from acute side effects of prior radiotherapy
No prior radiotherapy to 25% or more of bone marrow
No prior whole pelvic irradiation


At least 3 weeks since prior major surgery and recovered


At least 3 weeks since prior investigational agent
No concurrent proguanil, trimethoprim, co-trimoxazole, or pyrimethamine

Study is for people with:

Lung Cancer


Phase 2

Study ID:


Recruitment Status:

Unknown status



Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?


There are 7 Locations for this study

See Locations Near You

UCSF Cancer Center and Cancer Research Institute
San Francisco California, 94143, United States
Cancer Centers of Florida (U.S. Oncology)
Orlando Florida, 32806, United States
Louisiana State University School of Medicine
New Orleans Louisiana, 70112, United States
US Oncology - Albany Regional Cancer Center
Albany New York, 12208, United States
U.S. Oncology Research Inc.
Houston Texas, 77060, United States
Tyler Cancer Center
Tyler Texas, 75702, United States
Cancer Care Northwest
Spokane Washington, 99202, United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer


Phase 2

Study ID:


Recruitment Status:

Unknown status



How clear is this clinincal trial information?


Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.